Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats
/MDPI/2026
Why It Matters
This paper caught my attention because BPC-157 is popular in biohacking circles for gut and injury healing, but solid mechanistic evidence is sparse. This study shows it can accelerate surgical wound healing in the intestine—but this is rat data only. The 'stable gastric pentadecapeptide' marketing persists, yet we still lack human trials showing it survives oral dosing or works in people. Promising for understanding tissue repair mechanisms, but a long way from knowing if the capsules people buy actually do anything.
Key Findings
- BPC-157 reduced anastomotic leakage rates in rats when administered intraperitoneally at specific doses within the first week post-surgery
- Both systemic (intraperitoneal) and topical application showed healing benefits, suggesting multiple delivery routes may be effective
- Healing improvements were measurable within 7 days, showing relatively rapid tissue repair effects in the intestinal surgical model
- The study used rat models of intestinal anastomosis—a standard but limited proxy for human surgical healing
- No human data, no oral administration testing, and no bioavailability measurements—critical gaps for anyone considering supplementation